Good news for patient in Canada. Announced on 19-Mar, a new medicine called Cymbalta® (duloxetine HCl) has been approved is for the symptomatic relief of anxiety causing clinically significant distress in patients with Generalized Anxiety Disorder (GAD)
The approval is based on the studies of 2,700 non-depressed adults. The pool data shows improved core anxiety symptoms by 45% and significantly less replased of 13.7% in a 26 week study. Cool results as compared to those who took placebo.
What are the common side effects for these subjects? Nausea, dizziness, dry mouth, fatigue, constipation, somnolence, and increased sweating.
This medicine is produced by Eli Lilly Canada Inc. and Boehringer Ingelheim (Canada) Ltd.
Written by Andrew - Visit my post on
Panic Away Ebook Review by Joe Barry or
Cure Anxiety and Panic Attacks Ebook Review by Peter NagyTags: anxiety treatment, GAD, mental health
Entries (RSS)